CC-223
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CC-223, covering 2022-11-15 to 2022-11-15. Get the full timeline:
Most recent: Clinical Trial Update: Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma [Phase 1, Phase 2]